COMMUNIQUÉS West-GlobeNewswire

-
Actinium Announces New Clinical Trial to Study Effect of Actimab-A on Minimal Residual Disease in Postremission AML Patients
28/06/2018 -
Retrotope Receives FDA Clearance to Commence RT001 Phase 2/3 Clinical Trial in Patients with Infantile Neuroaxonal Dystrophy (INAD)
28/06/2018 -
BRACAnalysis® CDx Identifies Patients Who Respond to Lynparza® in SOLO-1 Study
28/06/2018 -
Amfora Unveils Broad Initiative to Develop Crops with Enhanced Protein Content for Food and Feed
28/06/2018 -
scPharmaceuticals Appoints Frederick Hudson to Board of Directors
28/06/2018 -
CLS Holdings USA Closes Acquisition of Oasis Cannabis
28/06/2018 -
Cellectar Announces Expansion of Diffuse Large B-Cell Lymphoma Cohort in CLR 131 Phase 2 Trial
28/06/2018 -
Flatiron Health CMO/CSO Joins CareDx Board of Directors
28/06/2018 -
Zafgen Announces Pricing of Offering of Common Stock
28/06/2018 -
Cocrystal Pharma Commences Enrollment and Initiates Patient Dosing in Phase 2a Study Evaluating CC-31244 for the Treatment of HCV
28/06/2018 -
Repligen Selects Purolite Life Sciences as Commercial Partner for New High Performance Ligand
28/06/2018 -
Kura Oncology Announces Pricing of $67 Million Public Offering of Common Stock
28/06/2018 -
MPI: Orphan Drug designation on Oncology Venture's dovitinib for Adenoid Cystic Carcinoma
28/06/2018 -
Kymab Announces Agreement to Evaluate KY1044, its Novel Antibody Targeting ICOS, and Anti-PD-L1 Immunotherapy for testing in Multiple Solid Tumors
28/06/2018 -
Helius Medical Technologies, Inc. Announces MRI Confirmatory Evidence of Neuroplastic Change after Investigational PoNS™ Treatment Presented at the 2018 Joint Annual Meeting ISMRM – ESMRMB in Paris, France
28/06/2018 -
Arsanis Provides Update Following Completion of Planned Interim Analysis of Phase 2 Clinical Trial of ASN100
28/06/2018 -
Capricor Therapeutics to Present at PPMD Annual Conference
28/06/2018 -
Neuronetics, Inc., Maker of NeuroStar® Advanced Therapy, Announces Pricing of Initial Public Offering
28/06/2018 -
Innovate Biopharmaceuticals Enters into an R&D Collaboration on Larazotide’s Corrective Effect on the Dysfunctional Intestinal Barrier and the Dysfunctional Microbiome in various Diseases with the University of Maryland School of Medicine
28/06/2018
Pages